Familial HypertriglyceridemiaSymptoms, Doctors, Treatments, Advances & More
Familial Hypertriglyceridemia Overview
Learn About Familial Hypertriglyceridemia
Familial hypertriglyceridemia is a common disorder passed down through families. It causes a higher-than-normal level of triglycerides (a type of fat) in a person's blood.
Type IV hyperlipoproteinemia
Familial hypertriglyceridemia is most likely caused by genetic variants combined with environmental factors. As a result, the condition clusters in families. How severe the disorder is can vary based on sex, age, hormone use, and dietary factors.
People with this condition also have high levels of very low density lipoprotein (VLDL). LDL cholesterol and HDL cholesterol are often low.
In most cases, familial hypertriglyceridemia is not noticeable until puberty or early adulthood. Obesity, hyperglycemia (high blood glucose levels), and high levels of insulin are often present as well. These factors may cause even higher triglyceride levels. Alcohol, a diet high in carbohydrates, and estrogen use can make the condition worse.
You are more likely to have this condition if you have a family history of hypertriglyceridemia or heart disease before age 50.
You may not notice any symptoms. Some people with the condition may have coronary artery disease at an early age.
The goal of treatment is to control conditions that can raise triglyceride levels. These include obesity, hypothyroidism, and diabetes.
Your provider may tell you to not drink alcohol. Certain birth control pills can raise triglyceride levels. Talk to your provider about your risk when deciding whether to take these medicines.
Treatment also involves avoiding excess calories and foods high in saturated fats and carbohydrates.
You may need to take medicine if your triglyceride levels stay high, even after making diet changes. Nicotinic acid, gemfibrozil, and fenofibrate will lower triglyceride levels in people with this condition.
UChicago Medicine River East
Michael Davidson is a Cardiologist practicing medicine in Chicago, Illinois. Dr. Davidson is rated as an Elite provider by MediFind in the treatment of Familial Hypertriglyceridemia. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Familial Hypertriglyceridemia, High Cholesterol, Heterozygous Familial Hypercholesterolemia (HeFH), Aortic Valve Replacement, and Transcatheter Aortic Valve Replacement (TAVR). Dr. Davidson is board certified in Practicing Since1986 and Cardiovascular Disease Internal Medicine. Dr. Davidson is currently accepting new patients.
Domino's Farms
Elif Oral is an Endocrinologist practicing medicine in Ann Arbor, Michigan. Dr. Oral is rated as an Elite provider by MediFind in the treatment of Familial Hypertriglyceridemia. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Familial Partial Lipodystrophy, Congenital Generalized Lipodystrophy, Familial Hypertriglyceridemia, Gastric Bypass, and Sleeve Gastrectomy. Dr. Oral is board certified in Endocrinology, Diabetes & Metabolism. Dr. Oral is currently accepting new patients.
Mount Sinai
Deepak Bhatt is a Cardiologist practicing medicine in New York, New York. Dr. Bhatt is rated as an Elite provider by MediFind in the treatment of Familial Hypertriglyceridemia. He is also highly rated in 45 other conditions, according to our data. His clinical expertise encompasses Heart Attack, Acute Coronary Syndrome, Coronary Heart Disease, Percutaneous Coronary Intervention (PCI), and Heart Bypass Surgery. Dr. Bhatt is currently accepting new patients.
Losing weight and keeping diabetes under control helps improve the outcome.
Complications may include:
- Pancreatitis
- Coronary artery disease
Screening family members for high triglycerides may detect the disease early.
Summary: VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the ...
Summary: The main objective of this study is to evaluate the effect of ION775 on fasting triglyceride (TG) levels in participants with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG).
Published Date: April 28, 2026
Published By: Michael A. Chen, MD, PhD, Associate Professor of Medicine, Division of Cardiology, Harborview Medical Center, University of Washington Medical School, Seattle, WA. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Bredefeld CL, Lau R, Hussain MM. Lipids and dyslipoproteinemia. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. St Louis, MO: Elsevier; 2022:chap 18.
Mora S, Martin SS. Measurement of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B, and low-density lipoprotein particle concentration. In: Ballantyne CM, ed. Clinical Lipidology: A Companion to Braunwald's Heart Disease. 3rd ed. Philadelphia, PA: Elsevier; 2024:chap 3.
Robinson JG. Disorders of lipid metabolism. In: Goldman L, Cooney KA, eds. Goldman-Cecil Medicine. 27th ed. Philadelphia, PA: Elsevier; 2024:chap 190.
Tokgözoglu L, Libby P. Lipoprotein disorders and cardiovascular disease. In: Bonow RO, Mann DL, Tomaselli GF, et al, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 13th ed. Philadelphia, PA: Elsevier; 2026:chap 25.
Writing Committee Members; Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. PMID: 41824552 pubmed.ncbi.nlm.nih.gov/41824552/.

